U.S. health regulators have warned Sanofi-Aventis SA’s U.S. unit for failing to submit reports of possible serious drug side effects in a timely manner.
In a Jan. 28 letter made public Tuesday, the Food and Drug Administration said an early response from the drugmaker and its “promised corrective actions are inadequate to address the deficiencies.” Get the full story »
